Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
GT Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of immuno-oncology therapies. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on engineered immune cell therapeutics designed to treat cancer. Its core strategy centers on leveraging proprietary platforms to enhance the cancer-fighting capabilities of natural killer (NK) cells and T cells, positioning the company within the rapidly evolving cell-based immunotherapy market.
The company’s primary revenue drivers are research and development activities, as it does not currently generate product revenue and relies on equity financing, grants, and strategic transactions. GT Biopharma’s product pipeline targets hematologic malignancies and solid tumors, with a focus on therapies intended for patients with limited treatment options. The company traces its origins to 1965 under a different corporate structure and name, later transitioning into a biotechnology-focused entity through a series of restructurings and strategic pivots, culminating in its current immuno-oncology focus.
Business Operations
GT Biopharma’s operations are centered on the research and development of its proprietary TriKE® (Tri-specific Killer Engager) and TetraKE® platforms, which are designed to activate and direct NK cells to selectively target cancer cells. These platforms form the foundation of its development pipeline and represent the company’s core technological assets. The company’s lead development programs are in preclinical and early clinical stages, and operational spending is primarily allocated to laboratory research, clinical trial preparation, and regulatory activities.
The company conducts its activities primarily through its corporate entity without large-scale commercial subsidiaries, and it does not currently operate manufacturing facilities for commercial production. GT Biopharma relies on third-party research organizations, academic collaborators, and contract manufacturers to support preclinical development and anticipated clinical trials. Its operations are primarily domestic, with international exposure limited to research collaborations and potential future clinical trial sites.
Strategic Position & Investments
GT Biopharma’s strategic direction is focused on advancing its immuno-oncology pipeline into clinical development while preserving capital and seeking strategic partnerships. Growth initiatives include the continued optimization of its TriKE® and TetraKE® technologies, expansion of indications for its lead candidates, and potential licensing or co-development agreements with larger pharmaceutical or biotechnology companies.
The company has historically pursued a lean operating model, prioritizing internal intellectual property development over large-scale acquisitions. Its investment strategy emphasizes platform scalability and the potential application of its technologies across multiple cancer indications. GT Biopharma is positioned in emerging sectors of immune cell engagers and NK cell–based therapies, which are areas of active interest within oncology research, though commercial validation remains in early stages.
Geographic Footprint
GT Biopharma is headquartered in the United States, with its principal executive offices located in California. The company’s operational footprint is predominantly domestic, reflecting its status as a development-stage biotechnology firm without commercial distribution or manufacturing operations.
International presence is currently limited and indirect, primarily through academic research collaborations and the potential for future multinational clinical trials. While the company’s technologies are intended for global oncology markets, its current operational and investment influence remains concentrated in North America, with no established regional offices outside the United States.
Leadership & Governance
GT Biopharma is led by an executive team with experience in biotechnology, life sciences finance, and corporate governance. The leadership’s stated strategic vision emphasizes disciplined capital management, advancement of proprietary immunotherapy platforms, and the pursuit of partnerships to accelerate clinical development.
Key executives include:
- Mitchell H. Gold – Executive Chairman of the Board
- Michael A. Breen – Interim Chief Executive Officer
- Michael D. Hart – Chief Financial Officer
- Steven A. Spector – Chief Scientific Officer
The board of directors oversees corporate strategy, regulatory compliance, and shareholder interests, with governance practices aligned to U.S. public company standards. Leadership continuity and execution remain important considerations given the company’s development-stage profile and reliance on external financing.